KMT2A and acute lymphoblastic leukemia: In diagnostic settings, specific miRNA expression profiles can serve as biomarkers for ALL, helping to distinguish between different subtypes (e.g., T-cell immunophenotype, BCR::ABL1, or KMT2A-rearranged ALL).7